⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
OTLKW
IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's Disease
accessnewswire.com
OTLK
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
globenewswire.com
OTLK
OTLKW
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
globenewswire.com
OTLK
OTLKW
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
globenewswire.com
OTLK
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
globenewswire.com
OTLK
Outlook Therapeutics Announces New Employment Inducement Grants
globenewswire.com
OTLK
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
globenewswire.com
OTLK